"A Company Dedicated to Diagnosing and Treating Inflammatory Diseases".

InflamaCORE has an experienced team of scientists and clinicians who are dedicated to this important clinical problem.  The company is associated with the University of Miami where both the administrative and scientific activities take place.  The company is on the verge of advancing an innovative treatment for acute neurological insults including stroke, brain trauma and spinal cord injury, and also the development of diagnostic tests to evaluate functional outcomes and help guide treatment strategies. Recently, the company has received a fast track STTR grant from the National Institutes of Health to move the company's lead drug forward to clinical trials.
In addition to the development of therapeutic interventions, InflamaCORE has also pioneered the development of biomarker assessment of body fluids that can be used to assess injury severity and therapeutic efficacy in individuals with these acute injuries and inflammatory diseases as Multiple Sclerosis, Major Depressive Disorder, Stroke, and Traumatic Brain Injury.  The combination of novel therapeutic interventions targeting inflammasome activation and biomarker discovery provides a powerful approach to assess treatments in patients with these devastating injuries and diseases.
InflamaCORE was founded in 2009 with the vision of developing novel therapeutic interventions to target abnormal inflammation following CNS injury and repair.  This starter company was formed by several University of Miami Miller School of Medicine faculty interested in the pathophysiology of treatment of brain and spinal cord injury.  Over the last several years, InflamaCORE has made significant progress in clarifying the role of the innate immune response in the pathogenesis of CNS injury.  Our scientists have discovered the molecular basis for abnormal inflammasome activation after different types of CNS injury including stroke, brain trauma and spinal cord injury.  InflamaCORE has developed novel biologics that targets the adaptor protein ASC present in multiple inflammasomes and ASC specks that contribute to a variety of innate immune inflammatory diseases and conditions. Blocking inflammasome assembly and ASC speck function will prevent damaging inflammation in a variety of diseases and conditions.